Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human copper-zinc superoxide dismutase
- Development stage
- Phase 2
- Lead developer
- Ferring Pharmaceuticals
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intra-rectal (enema), Possibly Intra-articular, Topical (for Certain Research/dermatologic Uses)
01
Overview
**Recombinant human copper-zinc superoxide dismutase (rhSOD1)** is a recombinant form of the human SOD1 enzyme, which catalyzes the dismutation of the superoxide radical (\(O_2^{\cdot-}\)) into hydrogen peroxide and molecular oxygen[1][2][4][7]. SOD1 is the primary intracellular antioxidant enzyme, present in the cytoplasm, nucleus, and various organelles. It is a 32 kDa homodimer that uses copper as the redox-active catalytic site and zinc for structural stability[1][2][4]. The drug is produced using recombinant DNA technology (such as expression in E. coli)[7], and acts as an antioxidant enzyme replacement therapy to lower cellular oxidative stress. Its mechanism is relevant to conditions involving excessive oxidative stress or inflammation, such as radiation-induced injury, ischemia-reperfusion injury, and chronic inflammatory states[1][2][3][5][7]. Clinical trials have explored its use for radiation-induced acute rectal injury and respiratory distress in newborns[3].
- Brand names
- Kang Fu Pen
- Other names
- human recombinant copper-zinc superoxide dismutaserecombinant human superoxide dismutaseHR-CuZnSODSODsuperoxide dismutase
Beyond the preview
Go deeper on recombinant human copper-zinc superoxide dismutase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human copper-zinc superoxide dismutase.